文献速递白血病淋巴瘤

EVOLVE项目:免疫治疗后谱系转换——白血病中一种新出现的复发形式的国际分析

Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia.
PubMed 文献 · Blood · 2025-01-01

EVOLVE项目通过国际合作纳入75例免疫治疗后谱系转换(LS)病例,其中53例(70.7%)为B细胞急性淋巴细胞白血病转为急性髓系白血病。LS多在最近一次免疫治疗后中位1.5个月出现,81.4%在6个月内发生,多数伴KMT2A重排(45例,64.3%),缓解率<40%,LS诊断后中位总生存4.8个月。

要点

  • 免疫治疗后谱系转换以B-ALL转为AML最常见(53/75,70.7%)。
  • LS多在最近免疫治疗后6个月内出现(81.4%),中位1.5个月。
  • LS后缓解率<40%,中位总生存4.8个月,结局普遍差。

核心结论

  • 该全球项目对免疫治疗后谱系变化进行了分类,并通过加深理解为进一步改善LS结局奠定基础。

研究设计与样本

  • 通过国际合作识别抗原靶向治疗(如CD19、CD22、CD38和CD7)后发生LS的病例,描述LS诊断方式、回顾治疗方法并分析总体结局。
  • 共评估75例LS,包括53例(70.7%)B-ALL转为AML、17例(22.7%)B-ALL转为MPAL/ALAL、5例(6.7%)罕见LS表现(即T-ALL转为AML),另描述10例免疫表型不完全改变的「谱系漂移」病例。

主要发现

  • 主要分析70例B-ALL转为AML或MPAL/ALAL的LS,LS在免疫治疗后中位1.5个月(范围0-36.5)出现,81.4%在最近一次免疫治疗后前6个月内出现。
  • 多数涉及KMT2A重排(45例,64.3%),也独特观察到其他罕见细胞遗传学和/或分子改变。
  • 治疗结局普遍差,缓解率<40%,LS诊断后中位总生存4.8个月。
  • 罕见免疫表型LS或谱系漂移者的结局同样差。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lineage switch (LS), defined as the immunophenotypic transformation of acute leukemia, has emerged as a mechanism of relapse after antigen-targeted immunotherapy, which is associated with dismal outcomes. Through an international collaborative effort, we identified cases of LS after a host of antigen-targeted therapies (eg, CD19, CD22, CD38, and CD7), described how LS was diagnosed, reviewed treatment approaches, and analyzed overall outcomes for this form of postimmunotherapy relapse. Collectively, 75 cases of LS were evaluated, including 53 (70.7%) cases of B-cell acute lymphoblastic leukemia (B-ALL) transforming to acute myeloid leukemia (AML), 17 (22.7%) cases of B-ALL transforming to mixed phenotypic acute leukemia (MPAL)/acute leukemias of ambiguous lineage (ALAL), and 5 (6.7%) cases of rare LS presentation (ie, T-cell ALL to AML). An additional 10 cases with incomplete changes in immunophenotype, referred to as "lineage drift" were also described. With a primary focus on the 70 cases of LS from B-ALL to AML or MPAL/ALAL, LS emerged at a median of 1.5 months (range, 0-36.5) after immunotherapy, with 81.4% presenting with LS within the first 6 months from the most proximal immunotherapy. Although most involved KMT2A rearrangements (n = 45, 64.3%), other rare cytogenetic and/or molecular alterations were uniquely observed. Treatment outcomes were generally poor, with remission rates of <40%. The median overall survival after LS diagnosis was 4.8 months. Outcomes were similarly poor for those with rare immunophenotypes of LS or lineage drift. This global initiative robustly categorizes lineage changes after immunotherapy and, through enhanced understanding, establishes a foundation for improving outcomes of LS.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Silbert SK, Rankin AW, Hoang CN, et al. Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia. Blood. 2025. PMID: 40193715. doi:10.1182/blood.2024026655

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。